August 2, 2019 - Fierce Pharma
Fujifilm has sealed the deal. With the completion of an $890 million, all-cash exchange with Biogen, the CDMO is now in possession of a biologics production facility in Denmark with about 800 employees. The 90,000-L capacity facility in Hillerød marks the fourth biologics manufacturing site for Tokyo-based Fujifilm Diosynth Biotechnologies, a partnership between Fujifilm and Mitsubishi. The site has six 15,000L bioreactors as well as assembly, labeling and packing capabilities, quality control laboratories and warehouses.
August 1, 2019 - Fierce Pharma
With Celgene making the big move under Bristol-Myers Squibb’s umbrella, the drugmaker is looking to clear its books before the merger. Two antitrust settlements totaling more than $100 million could help soothe BMS’ mind. Celgene will pay Mylan
to settle claims that it intentionally stifled generic competition for its blockbuster multiple myeloma med Revlimid and predecessor Thalomid. The Big Biotech refused to sell samples of the two drugs to generics makers, the lawsuit said—and those samples are necessary for copycats to win FDA approval.
July 31, 2019 - BioPharma Dive
The Trump administration on Wednesday proposed allowing the importation of lower-priced drugs from foreign countries in its latest bid to lower patient out-of-pocket costs. The proposal rests on the belief that manufacturers would offer imported drugs at a lower price if they sold them under a different National Drug Code than products designated for the U.S. market, a claim that analysts disputed. The pharmaceutical sector's leading trade group, meanwhile, opposed the plan on safety grounds.
July 30, 2019 - Outsourcing-Pharma
PRA Health Sciences has bought out its joint venture with Takeda, establishing a new subsidiary based in Japan – a rapidly growing market, says EVP.
July 29, 2019 - BioPharma Dive
Exact Sciences will buy fellow cancer technologies firm Genomic Health in a $2.8 billion deal announced Monday. Between the companies' currently marketed tests — Exact Sciences' Cologuard for colorectal cancer diagnosis and Genomic Health's Oncotype DX tests for predicting response to cancer treatments — executives forecast the combined company would generate $1.6 billion in revenue next year.